Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

Trial Profile

Assessment of Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Dec 2014

At a glance

  • Drugs AL 78898A (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms ASaP
  • Sponsors Potentia Pharmaceuticals
  • Most Recent Events

    • 24 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top